Tallimustine exhibits antitumor activity and can be used in the preparation of novel sustained-release anticancer injectable formulations composed of sustained-release microspheres and a solvent; it is also used in the preparation of a sustained-release anticancer injectable formulation containing an angiogenesis inhibitor, which consists of sustained-release microspheres and a solvent.